Singapore Oral Anti-Diabetes Drugs Market Analysis

Singapore Oral Anti-Diabetes Drugs Market Analysis


$ 3999

Singapore oral anti-diabetes drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Due to the rise in type 2 diabetes incidence, the market for oral antidiabetic medications is anticipated to have a considerable increase over the forecast period. The adoption of a bad lifestyle, environmental pollution, and a family history of diabetes disease all contribute to the market growth for oral antidiabetic medications. Some of the major key players in this market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Fresenius Kabi AG, etc.

ID: IN10SGPH349 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Dr. Netal Patel

Buy Now

Singapore Oral Anti-Diabetes Drugs Market Analysis Summary

Singapore Oral Anti-Diabetes Drugs Market is valued at around $57.1 Mn in 2022 and is projected to reach $84.6 Mn by 2030, exhibiting a CAGR of 5.03% during the forecast period 2023-2030.

Diabetes is a condition where there is a lack of insulin in the body and a high blood glucose level. Anti-diabetic medicines are prescription medications used to treat diabetes. It lowers blood sugar levels by activating gluconeogenic enzymes and glycogen phosphorylase, which reveals slower rates of glycogenolysis and gluconeogenesis. Since the healthcare industry places a high value on it, the market is anticipated to grow significantly throughout the forecast period. Due to the rise in type 2 diabetes incidence, the market for oral antidiabetic medications is anticipated to have a considerable increase over the forecast period. The adoption of a bad lifestyle, environmental pollution, and a family history of diabetes disease all contribute to the market growth for oral antidiabetic medications. The major key players in this market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals Plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Co., GSK Plc., and Bayer AG.

Market Dynamics

Market Growth Drivers

There will be 643 Mn adults with diabetes worldwide by 2030, up from the estimated 537 Mn in 2021. The rate of newly diagnosed instances of Type 1 and Type 2 diabetes is increasing, and this is likely due to several factors including obesity, a poor diet, and a lack of physical activity. As a result, this accelerates market expansion. With a prescription rate of 45–50% of all prescriptions, metformin continues to be the most often prescribed oral antidiabetic treatment globally. It is also used by more than 150 Mn individuals annually. Long-term good experiences with metformin use provide compelling evidence of the drug's therapeutic efficacy, safety, affordability, availability, high rate of adherence, and cost-effectiveness. As a result, it opens up opportunities for market expansion.

Market Restraints

The usage of oral diabetes medications has several side effects, including b12 deficiency, nausea, gas, bloating, diarrhea, and upset stomach. The market is hampered as a result. Moreover, the expensive treatment options undoubtedly slow market expansion.

Competitive Landscape

Key Players

  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals Plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Bristol Myers Squibb Co.
  • GSK Plc.
  • Bayer AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Oral Anti-Diabetes Drugs Market Segmentation

By Drug Class

  • Biguanides
  • Thiazolidinediones
  • Dipeptidyl Peptidase IV Inhibitors
  • α-Glucosidase Inhibitors
  • Insulin Secretagogues
  • Amylin Analog
  • Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
  • Glucagon-Like Peptide-1 Receptor Agonists
  • Others

By Type

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Others

By Distribution Channels

  • Hospital pharmacies
  • Retail Pharmacies
  • Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up